AgelessRx Releases New Scientific Study Citing the Critical Role of SF-36 in Geroscience Research

Ann Arbor, MI - AgelessRx, a leader in longevity and healthspan research, has published a groundbreaking study emphasizing the vital role of Quality of Life (QoL) data in geroscience clinical trials. The review paper, titled "The role of quality of life (QoL) data as an endpoint for collecting real world evidence within geroscience clinical trials," has been published in the prestigious journal Ageing Research Reviews. This study underscores the necessity of incorporating QoL assessments, such as the SF-36 survey, into longevity research to provide a comprehensive evaluation of the effectiveness of longevity interventions.

For too long, the focus of aging research has been primarily on biological markers such as inflammatory factors, muscle mass, and insulin resistance. While these markers are undeniably important, AgelessRx's new study argues that they do not paint a complete picture of healthy aging. The paper highlights the importance of considering social functioning, emotional wellbeing, role limitations, pain, and other aspects of QoL as critical components of the aging process.

The SF-36, a widely recognized and validated self-assessment tool, measures eight dimensions of health, including physical functioning, bodily pain, and mental health. AgelessRx’s study proposes that the SF-36 should be a gold standard test for assessing QoL changes in longevity interventions. The ease of administration and digital adaptability of the SF-36 make it an ideal candidate for real-world evidence collection, enabling researchers to gather meaningful data from participants in their natural environments.

Dr. Eric Verdin, CEO of the Buck Institute for Research on Aging and co-author of the study, stated, "Quality of Life assays have never been proposed as endpoints to validate gero-therapeutic interventions within longevity studies. Our research emphasizes that the perception of health and wellbeing is as crucial as biological improvements. This dual approach ensures that interventions not only extend lifespan but also enhance the quality of those extra years."

AgelessRx’s paper aligns with the recent high-profile guidelines provided by the Biomarkers of Aging Consortium, which classify the various biomarkers of aging. The study proposes integrating QoL data into these guidelines, arguing that perceived health improvements are as significant as biological ones. The subjective element of healthy aging, reflected through self-assessments, provides invaluable insight into how individuals feel about their health and wellbeing.

The incorporation of QoL data is particularly relevant in accelerating progress in the longevity field. Traditional study designs often suffer from complexity, high costs, and lengthy durations. Real-world evidence, collected through digital wearables, electronically administered tests, and at-home blood kits, offers a faster, more efficient alternative. This approach democratizes access to longevity interventions, allowing data collection from a more diverse and extensive participant pool.

Matt Kaeberlein, CEO of Optispan and another co-author added, "Our study signifies a paradigm shift in how we evaluate longevity interventions. By prioritizing QoL data, we can accelerate the validation process of FDA-approved interventions with repurposing potential, such as rapamycin, metformin, and LDN. This will enable quicker, more inclusive access to treatments that can significantly enhance healthspan."

AgelessRx is at the forefront of this effort, already collecting SF-36 QoL data from patients using various longevity therapies. This patient-centric approach ensures that the real-world benefits of these interventions are thoroughly understood and validated.

Co-authors of the study include Girish Harinath, an expert in geroscience, and Dr. Sajad Zalzala, a leading clinician in longevity science. Their combined expertise and commitment to advancing geroscience underscore the study’s importance and potential impact.

In conclusion, AgelessRx’s study is a pivotal step towards a more holistic approach in longevity research. By advocating for the inclusion of QoL assessments alongside traditional biomarkers, the study promises to enhance the effectiveness of longevity interventions, ultimately leading to healthier, more fulfilling lives for all.

About AgelessRx

AgelessRx is at the forefront of the longevity revolution, offering cutting-edge solutions and preventive treatments aimed at extending life expectancy and enhancing healthspan. Through its online platform, AgelessRx provides easy access to innovative healthcare services, with an emphasis on customer satisfaction, affordability, and the pursuit of a future where extended healthspan is a reality for everyone.

Media Contact

Name
AgelessRx
Contact name
Anar Isman
Contact phone
650-503-9990
Contact address
2370 E Stadium Blvd #2049
City
Ann Arbor
State
MI
Zip
48104
Country
United States
Url
https://www.agelessrx.com/

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.